- IBD
-
Why is it so difficult to evaluate faecal microbiota transplantation as a treatment for ulcerative colitis?
-
Natalie Grace Fairhurst, Simon P. L. Travis
-
Intest Res 2018;16(2):209-215. Published online April 30, 2018
-
DOI: https://doi.org/10.5217/ir.2018.16.2.209
-
-
 Abstract
 PDF PubReader ePub
Faecal microbiota transplantation (FMT) has recently re-emerged as a viable therapeutic option for colonic disorders. Its efficacy has been proved in the treatment of Clostridium difficile infection which has encouraged research into the use of FMT for other disorders involving gut dysbiosis, such as ulcerative colitis (UC), a chronic inflammatory disease characterized by relapsing and remitting colonic inflammation. Although the FMT protocol for C. difficile treatment is well established, there are numerous additional factors to consider when applying FMT to treat inflammatory diseases. Various studies have attempted to address these factors but technical inconsistency between reports has resulted in a failure to achieve clinically significant findings. Case reports of FMT in UC have shown favorable outcomes yet demonstrating these effects on a larger scale has proved difficult. The following review aims to explore these issues and to analyze why they may be hindering the progression of FMT therapy in UC. -
Citations
Citations to this article as recorded by  - The Role of Fecal Microbiota Transplantation in the Induction of Remission in Ulcerative Colitis
Adam Saleh, Shyon Parsa, Manuel Garza, Eamonn M.M. Quigley, Bincy P. Abraham
Digestive Diseases.2023; 41(4): 656. CrossRef - Probiotic-Based Intervention in the Treatment of Ulcerative Colitis: Conventional and New Approaches
Jana Štofilová, Monika Kvaková, Anna Kamlárová, Emília Hijová, Izabela Bertková, Zuzana Guľašová
Biomedicines.2022; 10(9): 2236. CrossRef - Finding intestinal fortitude: Integrating the microbiome into a holistic view of depression mechanisms, treatment, and resilience
M.C. Flux, Christopher A. Lowry
Neurobiology of Disease.2020; 135: 104578. CrossRef - In Situ Profiling of the Three Dominant Phyla Within the Human Gut Using TaqMan PCR for Pre-Hospital Diagnosis of Gut Dysbiosis
Young Jae Jo, Setu Bazie Tagele, Huy Quang Pham, YeonGyun Jung, Jerald Conrad Ibal, SeungDae Choi, Gi-Ung Kang, Sowon Park, Yunkoo Kang, Seung Kim, Hong Koh, Jae-Ho Shin
International Journal of Molecular Sciences.2020; 21(6): 1916. CrossRef - Gut microbiota in ulcerative colitis: insights on pathogenesis and treatment
Xiao Yan Guo, Xin Juan Liu, Jian Yu Hao
Journal of Digestive Diseases.2020; 21(3): 147. CrossRef - Potential Implications of Gut Microbiota in Drug Pharmacokinetics and Bioavailability
Stephanie A. Flowers, Shubha Bhat, James C. Lee
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy.2020; 40(7): 704. CrossRef - Efficacy of fecal microbiota therapy in steroid dependent ulcerative colitis: a real world intention-to-treat analysis
Ajit Sood, Ramit Mahajan, Garima Juyal, Vandana Midha, Charanpreet Singh Grewal, Varun Mehta, Arshdeep Singh, Mohan C Joshi, Vikram Narang, Kirandeep Kaur, Hasrat Sidhu
Intestinal Research.2019; 17(1): 78. CrossRef - Multi-session fecal microbiota transplantation using colonoscopy has favorable outcomes for the treatment of
steroid-dependent ulcerative colitis
Young-Seok Cho
Intestinal Research.2019; 17(1): 6. CrossRef - Long-Term Safety and Efficacy of Fecal Microbiota Transplant in Active Ulcerative Colitis
Xiao Ding, Qianqian Li, Pan Li, Ting Zhang, Bota Cui, Guozhong Ji, Xiang Lu, Faming Zhang
Drug Safety.2019; 42(7): 869. CrossRef
-
7,731
View
-
79
Download
-
11
Web of Science
-
9
Crossref
- IBD
-
Are Truelove and Witts criteria for diagnosing acute severe colitis relevant for the Indian population? A prospective study
-
Saransh Jain, Saurabh Kedia, Sawan Bopanna, Dawesh P Yadav, Sandeep Goyal, Peush Sahni, Sujoy Pal, Nihar Ranjan Dash, Govind Makharia, Simon P. L. Travis, Vineet Ahuja
-
Intest Res 2018;16(1):69-74. Published online January 18, 2018
-
DOI: https://doi.org/10.5217/ir.2018.16.1.69
-
-
Abstract
PDFPubReaderePub
- <b>Background/Aims</b><br/>
Truelove and Witts criteria have been used to define acute severe colitis since the 1950s. However, hemoglobin (an additional criterion of the definition) levels in the general population in developing countries are lower than in the population of developed countries. We aimed to determine the relevance of Truelove and Witts criteria in the Indian population. MethodsConsecutive patients with acute severe colitis satisfying the Truelove and Witts criteria, hospitalized at a single center between April 2015 and December 2016 were included. All patients received intravenous corticosteroids and 16 required colectomy. The hemoglobin levels at admission were subsequently excluded from the classification criteria, and the effect this had on the criteria for diagnosis was determined. ResultsOut of 61 patients of acute severe colitis diagnosed according to the original Truelove and Witts criteria, 12 patients (20%) had 1 additional criterion, 33 (54%) had 2 additional criteria and 16 (26%) had 3 or more additional criteria in addition to 6 or more blood stained stools on admission. On excluding hemoglobin as an additional criterion from the Truelove and Witts definition, all patients still met the criteria for acute severe colitis. ConclusionsTruelove and Witts criteria can be used to define acute severe colitis in India, despite lower mean hemoglobin in the native population.
-
Citations
Citations to this article as recorded by
-
8,939
View
-
84
Download
-
6
Web of Science
-
7
Crossref
-
'Lemonade Legs': Why do Some Patients Get Profound Hypomagnesaemia on Proton-Pump Inhibitors?
-
Nathan S. S. Atkinson, D. John M. Reynolds, Simon P. L. Travis
-
Intest Res 2015;13(3):227-232. Published online June 9, 2015
-
DOI: https://doi.org/10.5217/ir.2015.13.3.227
-
-
Abstract
PDFPubReader
Proton pump inhibitors (PPIs) are widely used though an association with hypomagnesaemia and hypocalcaemia has only been described since 2006. Patients typically present after years of stable dosing with musculoskeletal, neurological or cardiac arrhythmic symptoms, but it is likely that many cases are under-recognised. Magnesium levels resolve rapidly on discontinuation of PPI therapy and hypomagnesaemia recurs rapidly on rechallenge with any agent in the class. The cellular mechanisms of magnesium homeostasis are increasingly being understood, including both passive paracellular absorption through claudins and active transcellular transporters, including the transient receptor potential channels (TRPM6) identified in the intestine and nephron. PPIs may alter luminal pH by modulating pancreatic secretions, affecting non-gastric H+K+ATPase secretion, altering transporter transcription or channel function. A small reduction in intestinal absorption appears pivotal in causing cumulative deficiency. Risk factors have been associated to help identify patients at risk of this effect but clinical vigilance remains necessary for diagnosis. -
Citations
Citations to this article as recorded by - Use of Acid-Suppression Therapy and Odds of Migraine and Severe Headache in the National Health and Nutrition Examination Survey
Margaret Slavin, Cara L. Frankenfeld, Alexander B. Guirguis, Elizabeth K. Seng
Neurology Clinical Practice.2024;[Epub] CrossRef - Magnesium Homeostasis
Aubrey R. Morrison
Clinical Journal of the American Society of Nephrology.2023; 18(7): 969. CrossRef - Risk of urinary stone formation associated to proton pump inhibitors: A systematic review and metanalysis
Rawa Bapir, Kamran Hassan Bhatti, Ahmed Eliwa, Herney Andrés García-Perdomo, Nazim Gherabi, Derek Hennessey, Vittorio Magri, Panagiotis Mourmouris, Adama Ouattara, Gianpaolo Perletti, Joseph Philipraj, Konstantinos Stamatiou, Musliu Adetola Tolani, Lazaro
Archivio Italiano di Urologia e Andrologia.2022; 94(4): 507. CrossRef - An overview of diagnosis and management of drug‐induced hypomagnesemia
George Liamis, Ewout J. Hoorn, Matilda Florentin, Haralampos Milionis
Pharmacology Research & Perspectives.2021;[Epub] CrossRef - Effects of Proton Pump Inhibitors on the Gastrointestinal Microbiota in Gastroesophageal Reflux Disease
Yi-Chao Shi, Shun-Tian Cai, Ya-Ping Tian, Hui-Jun Zhao, Yan-Bing Zhang, Jing Chen, Rong-Rong Ren, Xi Luo, Li-Hua Peng, Gang Sun, Yun-Sheng Yang
Genomics, Proteomics & Bioinformatics.2019; 17(1): 52. CrossRef - Atrial fibrillation and gastrooesophageal reflux disease: association mechanisms, treatment approaches
O. N. Antropova, N. V. Pyrikova, I. V. Osipova
Russian Journal of Cardiology.2019; (7): 103. CrossRef - Do stop me now: gastric acid-reducing drugs following renal transplantation
Ines Held, Rhodri Pyart
Journal of Kidney Care.2018; 3(1): 6. CrossRef - Magnesium homeostasis in cattle: absorption and excretion
Holger Martens, Sabine Leonhard-Marek, Monika Röntgen, Friederike Stumpff
Nutrition Research Reviews.2018; 31(1): 114. CrossRef - A Review of the Novel Application and Potential Adverse Effects of Proton Pump Inhibitors
Li-Yuan Yu, Lu-Ning Sun, Xue-Hui Zhang, Yue-Qi Li, Lei Yu, Zi-Qing-Yun Yuan, Ling Meng, Hong-Wen Zhang, Yong-Qing Wang
Advances in Therapy.2017; 34(5): 1070. CrossRef - Prokinetics for the treatment of functional dyspepsia: Bayesian network meta-analysis
Young Joo Yang, Chang Seok Bang, Gwang Ho Baik, Tae Young Park, Suk Pyo Shin, Ki Tae Suk, Dong Joon Kim
BMC Gastroenterology.2017;[Epub] CrossRef - Proton Pump Inhibitors Should be Used with Caution in Critically Ill Patients to Prevent the Risk of Clostridium difficile Infection
Jung Hwa Min, You Sun Kim
Gut and Liver.2016; 10(4): 493. CrossRef - Impact of Long-Term Proton Pump Inhibitor Therapy on Gut Microbiota in F344 Rats: Pilot Study
Cheol Min Shin, Nayoung Kim, Yong Sung Kim, Ryoung Hee Nam, Ji Hyun Park, Dong Ho Lee, Yeong-Jae Seok, Yeon-Ran Kim, Joo-Hyon Kim, Jung Min Kim, Joo Sung Kim, Hyun Chae Jung
Gut and Liver.2016; 10(6): 896. CrossRef
-
7,325
View
-
68
Download
-
12
Web of Science
-
12
Crossref
|
KASID
